A-366,833

A-366,833
Identifiers
	IUPAC name 5-[(1R,5S)-3,6-Diazabicyclo[3.2.0]hept-6-yl]pyridine-3-carbonitrile;
CAS Number	370882-41-0 ;
PubChem CID	9834234;
ChemSpider	8009955 ;
UNII	6XRK9HTJ6M;
ChEMBL	ChEMBL239931 ;
Chemical and physical data
Formula	C11H12N4
Molar mass	200.245 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	101.4–102.9 °C (214.5–217.2 °F)
	SMILES N#CC1=CN=CC(N2[C@]3([H])CNC[C@]3([H])C2)=C1;
	InChI InChI=1S/C11H12N4/c12-2-8-1-10(5-13-3-8)15-7-9-4-14-6-11(9)15/h1,3,5,9,11,14H,4,6-7H2/t9-,11-/m1/s1 ; Key:GPXAWLDGWSBLKM-MWLCHTKSSA-N ;
	(what is this?) (verify)

A-366,833 is a drug developed by Abbott, which acts as an agonist at neural nicotinic acetylcholine receptors selective for the α4β2 subtype, and has been researched for use as an analgesic, although it has not passed clinical trials.^[2] Its structure has a nicotinonitrile (3-cyanopyridine) core bound through C5 to the N6 of (1R,5S)-3,6-diazabicyclo[3.2.0]heptane.^[3]

References

^ Ji J, Schrimpf MR, Sippy KB, Bunnelle WH, Li T, Anderson DJ, et al. (November 2007). "Synthesis and structure-activity relationship studies of 3,6-diazabicyclo[3.2.0]heptanes as novel alpha4beta2 nicotinic acetylcholine receptor selective agonists". Journal of Medicinal Chemistry. 50 (22): 5493–508. doi:10.1021/jm070755h. PMID 17929796.
^ Romanelli MN, Gratteri P, Guandalini L, Martini E, Bonaccini C, Gualtieri F (June 2007). "Central nicotinic receptors: structure, function, ligands, and therapeutic potential". ChemMedChem. 2 (6): 746–67. doi:10.1002/cmdc.200600207. PMID 17295372. S2CID 34763474.
^ Ji J, Bunnelle WH, Anderson DJ, Faltynek C, Dyhring T, Ahring PK, et al. (October 2007). "A-366833: a novel nicotinonitrile-substituted 3,6-diazabicyclo[3.2.0]-heptane alpha4beta2 nicotinic acetylcholine receptor selective agonist: Synthesis, analgesic efficacy and tolerability profile in animal models". Biochemical Pharmacology. 74 (8): 1253–62. doi:10.1016/j.bcp.2007.08.010. PMID 17854775.

This analgesic-related article is a stub. You can help Wikipedia by expanding it.

[1] Ji J, Schrimpf MR, Sippy KB, Bunnelle WH, Li T, Anderson DJ, et al. (November 2007). "Synthesis and structure-activity relationship studies of 3,6-diazabicyclo[3.2.0]heptanes as novel alpha4beta2 nicotinic acetylcholine receptor selective agonists". Journal of Medicinal Chemistry. 50 (22): 5493–508. doi:10.1021/jm070755h. PMID 17929796.

[2] Romanelli MN, Gratteri P, Guandalini L, Martini E, Bonaccini C, Gualtieri F (June 2007). "Central nicotinic receptors: structure, function, ligands, and therapeutic potential". ChemMedChem. 2 (6): 746–67. doi:10.1002/cmdc.200600207. PMID 17295372. S2CID 34763474.

[3] Ji J, Bunnelle WH, Anderson DJ, Faltynek C, Dyhring T, Ahring PK, et al. (October 2007). "A-366833: a novel nicotinonitrile-substituted 3,6-diazabicyclo[3.2.0]-heptane alpha4beta2 nicotinic acetylcholine receptor selective agonist: Synthesis, analgesic efficacy and tolerability profile in animal models". Biochemical Pharmacology. 74 (8): 1253–62. doi:10.1016/j.bcp.2007.08.010. PMID 17854775.

[2]

[3]

[1]

Identifiers

IUPAC name 5-[(1R,5S)-3,6-Diazabicyclo[3.2.0]hept-6-yl]pyridine-3-carbonitrile
CAS Number	370882-41-0^Y
PubChem CID	9834234
ChemSpider	8009955^Y
UNII	6XRK9HTJ6M
ChEMBL	ChEMBL239931^Y
Chemical and physical data
Formula	C₁₁H₁₂N₄
Molar mass	200.245 g·mol⁻¹
3D model (JSmol)	Interactive image
Melting point	101.4–102.9 °C (214.5–217.2 °F) ^[1]
SMILES N#CC1=CN=CC(N2[C@]3([H])CNC[C@]3([H])C2)=C1
InChI InChI=1S/C11H12N4/c12-2-8-1-10(5-13-3-8)15-7-9-4-14-6-11(9)15/h1,3,5,9,11,14H,4,6-7H2/t9-,11-/m1/s1^N Key:GPXAWLDGWSBLKM-MWLCHTKSSA-N^N
^NY (what is this?) (verify)